Itraconazol Alter

Itraconazole, the active ingredient in Itraconazol Alter, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of serious fungal infections—including dermatophytosis, candidiasis, blastomycosis, histoplasmosis and aspergillosis—when prescribed by a qualified healthcare professional. The product complies with EU quality standards and is manufactured under GMP conditions.

GNH USA supplies Itraconazol Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company provides reliable logistics and regulatory support for global distribution.

Itraconazole is used to treat systemic fungal infections by targeting the causative organisms in various disease categories.

Dermatophytosis: resolves skin and nail infections caused by dermatophyte fungi, reducing lesions and preventing spread. Candidiasis: treats oral, esophageal and systemic candidal infections, alleviating symptoms and eradicating the pathogen. Blastomycosis: combats Blastomyces dermatitidis infection, improving pulmonary and disseminated disease outcomes. Histoplasmosis: manages Histoplasma capsulatum infection, especially in immunocompromised patients, to control respiratory and systemic manifestations. Aspergillosis: addresses invasive Aspergillus infections, limiting fungal growth and aiding recovery in high‑risk individuals.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset that may improve with food. - Headache: transient pain often resolving without intervention. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis requiring monitoring. - Congestive heart failure: worsening of pre‑existing heart failure or new fluid retention. - Severe allergic reaction: anaphylaxis or angioedema demanding immediate care.

When prescribing itraconazole, several precautions should be observed to minimize risks and ensure safe use. - Liver function: assess baseline hepatic enzymes and monitor periodically during therapy. - Cardiac status: avoid use in patients with existing congestive heart failure or monitor closely. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Pregnancy and lactation: consider potential risks and discuss with a qualified obstetrician before use. - Gastrointestinal absorption: advise patients to take with a full meal or acidic beverage to enhance bioavailability. - Store at below 25°C: keep in the original container, protect from moisture and light.

Itraconazole interacts with several medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce itraconazole exposure. - Certain statins (e.g., simvastatin, lovastatin): increased risk of myopathy and rhabdomyolysis. - QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase itraconazole levels, requiring dose adjustment. - Anticoagulants (e.g., warfarin): potential alteration of INR, necessitating closer monitoring. - Oral hypoglycemics (e.g., sulfonylureas): possible enhanced hypoglycemic effect.